PGY-4 Roadmap: Preparing for Life After Dermatology Residency
Welcome to the final installment of The Roadmap Series: Key Learnings by Residency Year. PGY-4 Roadmap: Preparing for Life After Residency is a concise, practical guide to help final-year dermatology residents turn years of accumulated experience into confident, independent practice. Inside you’ll find focused advice on owning continuity care and clinic systems, mastering the essentials of codin …
Welcome to the final installment of The Roadmap Series: Key Learnings by Residency Year. PGY-4 Roadmap: Preparing for Life After Residency is a concise, practical guide to help final-year dermatology residents turn years of accumulated experience into confident, independent practice. Inside you’ll find focused advice on owning continuity care and clinic systems, mastering the essentials of codin … Continue reading "PGY-4 Roadmap: Preparing for Life After Dermatology Residency"
Transitioning from a third-year residency into the professional workforce is a major milestone that requires a strategic approach. Unlike fellowship tracks, which offer an additional year of buffer, going straight into the workforce demands immediate and thoughtful preparation. By following these core principles, you can navigate the complexities of the job market and secure a position that aligns … 
When a patient reveals they went online for health information, it’s tempting for a clinician to inwardly groan. Fears of self-diagnosis or misinformation about diagnosed conditions can make clinicians concerned when patients seek medical information through online forums and social media. Yet these virtual communities are incredibly popular, most notably Reddit and its discussion forums.
A … 
At the 2026 ODAC Dermatology Conference, we had the privilege of learning about chronic spontaneous urticaria (CSU) from Dr. Adam Friedman, MD, FAAD, Professor and Chair of Dermatology at The George Washington University School of Medicine. CSU can be a maddening, exhausting condition for patients, with a relapsing disease course and without identifiable triggers. Given that symptoms are often abs … 
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta …